Cellular signalling · 2026
Dual regulation of NFS1 by TRIM67-mediated degradation and CEBPA-driven transcription modulates colorectal cancer progression.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Bing, Huang Xiaofang, Xing Yulong, Jiao Wei, Jiang Jianhua, Liu Gang, Li Guochao, Li Qinquan, Yang Chunyu, Shi Lianghui
Аннотация
BACKGROUND: NFS1 cysteine desulfurase (NFS1) a critical enzyme in iron‑sulfur (Fe-S) cluster biogenesis and mitochondrial iron homeostasis, plays a pivotal role in the dysregulation of iron metabolism, a recognized hallmark of cancer. However, the specific role and regulatory mechanisms of NFS1 in colorectal cancer (CRC) remain poorly understood. This study aimed to elucidate the function of NFS1 in CRC and to uncover the upstream molecular pathways governing its expression.
METHODS: The expression of NFS1 in CRC was comprehensively analyzed using public databases (TIMER2.0, TCGA, and TNMplot) and validated in clinical tissue samples and CRC cell lines by quantitative real-time PCR and Western blotting. Loss- and gain-of-function experiments were conducted in SW620 and LoVo cells to assess the effects of NFS1 on cell proliferation, migration, stemness, apoptosis, and ferroptosis, which were evaluated using Cell Counting Kit-8 (CCK-8), EdU, Transwell migration, sphere formation, flow cytometry, and specific metabolic assays. The regulatory mechanisms were investigated through cycloheximide (CHX) chase, ubiquitination, dual-luciferase reporter, and chromatin immunoprecipitation (ChIP) assays. Finally, a xenograft mouse model was established to validate the findings in vivo.
RESULTS: NFS1 was significantly upregulated in CRC tissues and cell lines, with its expression associated with tumor-node-metastasis grade, lymph node metastasis, and tumor size. In vitro, NFS1 silencing suppressed CRC cell proliferation, migration, and stemness, while promoting apoptosis and ferroptosis. Mechanistically, tripartite motif containing 67 (TRIM67) directly interacted with NFS1 and promoted its ubiquitination and protein degradation. Conversely, the transcription factor CCAAT/enhancer-binding protein alpha (CEBPA) was found to bind to the NFS1 promoter and positively regulate its transcription. Functional rescue experiments demonstrated that the anti-tumor effects of TRIM67 overexpression or CEBPA silencing were effectively reversed by concurrent NFS1 overexpression. Further, the in vivo xenograft model confirmed that CEBPA knockdown inhibited tumor growth and tumor lung metastasis by downregulating NFS1.
CONCLUSION: In CRC, the oncogenic transcription factor CEBPA positively regulated NFS1 transcription, while the E3 ligase TRIM67 promoted its ubiquitination and degradation. Both TRIM67 overexpression and CEBPA silencing suppressed the malignant progression of CRC by downregulating NFS1, highlighting the TRIM67/CEBPA/NFS1 axis as a potential therapeutic target.
METHODS: The expression of NFS1 in CRC was comprehensively analyzed using public databases (TIMER2.0, TCGA, and TNMplot) and validated in clinical tissue samples and CRC cell lines by quantitative real-time PCR and Western blotting. Loss- and gain-of-function experiments were conducted in SW620 and LoVo cells to assess the effects of NFS1 on cell proliferation, migration, stemness, apoptosis, and ferroptosis, which were evaluated using Cell Counting Kit-8 (CCK-8), EdU, Transwell migration, sphere formation, flow cytometry, and specific metabolic assays. The regulatory mechanisms were investigated through cycloheximide (CHX) chase, ubiquitination, dual-luciferase reporter, and chromatin immunoprecipitation (ChIP) assays. Finally, a xenograft mouse model was established to validate the findings in vivo.
RESULTS: NFS1 was significantly upregulated in CRC tissues and cell lines, with its expression associated with tumor-node-metastasis grade, lymph node metastasis, and tumor size. In vitro, NFS1 silencing suppressed CRC cell proliferation, migration, and stemness, while promoting apoptosis and ferroptosis. Mechanistically, tripartite motif containing 67 (TRIM67) directly interacted with NFS1 and promoted its ubiquitination and protein degradation. Conversely, the transcription factor CCAAT/enhancer-binding protein alpha (CEBPA) was found to bind to the NFS1 promoter and positively regulate its transcription. Functional rescue experiments demonstrated that the anti-tumor effects of TRIM67 overexpression or CEBPA silencing were effectively reversed by concurrent NFS1 overexpression. Further, the in vivo xenograft model confirmed that CEBPA knockdown inhibited tumor growth and tumor lung metastasis by downregulating NFS1.
CONCLUSION: In CRC, the oncogenic transcription factor CEBPA positively regulated NFS1 transcription, while the E3 ligase TRIM67 promoted its ubiquitination and degradation. Both TRIM67 overexpression and CEBPA silencing suppressed the malignant progression of CRC by downregulating NFS1, highlighting the TRIM67/CEBPA/NFS1 axis as a potential therapeutic target.